Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies
Preclinical
Abstract
In silico and in vivo studies showed that bitter melon (Momordica charantia)-derived compounds act as antidiabetics, modulating glucose-handling targets, supporting the molecular basis of the herb's hypoglycaemic effect.
Referenced for these plants
How to cite
Elekofehinti, O.O., Ariyo, E.O., Akinjiyan, M.O., Olayeriju, O.S. and others (2018) 'Potential use of bitter melon (Momordica charantia) derived compounds as antidiabetics: In silico and in vivo studies', Pathophysiology, 25(4), pp. 327-333. doi:10.1016/j.pathophys.2018.05.003
This reference is part of the evidence base for the Omnia Sana plant database. Source links open the original publication; Omnia Sana does not host third-party content.